Most Recent
The High Court has declined to take up Mylan's challenge to a Full Court ruling upholding the invalidity of three patents for its blockbuster cholesterol drug Lipidil.
US cryptocurrency maker Ripple Labs has hit back at an intellectual property lawsuit brought by the Australian company behind the ubiquitous PayID mobile banking system, saying its PayID trade mark is neither substantially identical nor deceptively similar to the Aussie mark.
The maker of pain killer Maxigesic is taking its long-running battle with Nuromol manufacturer Reckitt Benckiser to an appeals court after a recent ruling that its advertising misled consumers by claiming Maxigesic provided better, faster and more effective pain relief than paracetamol or ibuprofen.
A judge has shot down Monster Energy's opposition to Japanese software company Mixi registering the 'Monster Strike' trade mark in Australia for its popular video game of the same name, the second judge to find the energy drink maker's standalone 'Monster' mark does not have a significant reputation in Australia.
Women's fashion designer Pinnacle Runway must pay indemnity costs for pursuing what a judge has described as an "ill-advised" trade mark infringement lawsuit against a rival that "cried out to be settled".
A court has issued an order restraining US blockchain company Ripple Labs from advertising its PayID system to Aussies, two days after the company agreed to geoblock its website within Australia.
US blockchain technology firm Ripple Labs has said that it will rebrand and block access to allegedly infringing websites as it seeks to rapidly resolve an intellectual property dispute launched over the PayID trade mark.
The company behind the ubiquitous mobile banking PayID system has filed Federal Court trade mark proceedings against a US blockchain technology firm over its global real-time payment service.
AFT Pharmaceuticals has suffered another blow over its Maxigesic advertisements, with a judge finding the marketing material misled consumers by claiming to provide better, faster and more effective pain relief than paracetamol or ibuprofen.
Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.